LEGEND BIOTECH CORP
NASDAQ: LEGN (Legend Biotech Corporation)
Last update: yesterday, 9:38AM23.59
0.07 (0.30%)
| Previous Close | 23.52 |
| Open | 23.41 |
| Volume | 995,865 |
| Avg. Volume (3M) | 1,993,456 |
| Market Cap | 4,363,103,744 |
| Price / Earnings (Forward) | 112.36 |
| Price / Sales | 4.21 |
| Price / Book | 4.34 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2026 |
| Profit Margin | -29.95% |
| Operating Margin (TTM) | -25.97% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 107.50% |
| Total Debt/Equity (MRQ) | 35.65% |
| Current Ratio (MRQ) | 5.20 |
| Operating Cash Flow (TTM) | -263.30 M |
| Levered Free Cash Flow (TTM) | -202.32 M |
| Return on Assets (TTM) | -8.77% |
| Return on Equity (TTM) | -20.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Legend Biotech Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.31% |
| % Held by Institutions | 47.92% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Hhlr Advisors, Ltd. | 31 Dec 2025 | 5,984,550 |
| Davern Capital Partners, Lp | 31 Dec 2025 | 1,056,668 |
| Matthews International Capital Management Llc | 31 Dec 2025 | 956,824 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (Barclays, 239.13%) | Buy |
| Median | 62.00 (162.82%) | |
| Low | 49.00 (Morgan Stanley, 107.72%) | Buy |
| Average | 63.67 (169.90%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 19.06 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 11 Mar 2026 | 49.00 (107.72%) | Buy | 20.27 |
| RBC Capital | 11 Mar 2026 | 62.00 (162.82%) | Buy | 20.27 |
| Barclays | 04 Feb 2026 | 80.00 (239.13%) | Buy | 16.65 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |